Navigation Links
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Date:8/31/2007

ment.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, preclinical and internal and partnered clinical programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, Arena's planned clinical trials may not proceed at the time Arena expects or at all, the results of preclinical studies or clinical trials may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7228

Director, Corporate C
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3Ascension Orthopedics Hires Key Senior Executives 2Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging 2Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging 3Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging 4Stanford researchers publish comprehensive model for medical device development 9055 1Stanford researchers publish comprehensive model for medical device development 9055 2Stanford researchers publish comprehensive model for medical device development 9055 3Perot Systems Wins Over 24119 Million CDC Contract 50319 1Perot Systems Wins Over 24119 Million CDC Contract 50319 2Lumension Integrates With Network Frontiers 26apos 3B Unified Compliance Framework To Simplify Compliance Challenges Reduce Costs And Harmonize Cont 50316 1Lumension Integrates With Network Frontiers 26apos 3B Unified Compliance Framework To Simplify Compliance Challenges Reduce Costs And Harmonize Cont 50316 2Lumension Integrates With Network Frontiers 26apos 3B Unified Compliance Framework To Simplify Compliance Challenges Reduce Costs And Harmonize Cont 50316 3Lumension Integrates With Network Frontiers 26apos 3B Unified Compliance Framework To Simplify Compliance Challenges Reduce Costs And Harmonize Cont 50316 4Lumension Integrates With Network Frontiers 26apos 3B Unified Compliance Framework To Simplify Compliance Challenges Reduce Costs And Harmonize Cont 50316 5Lumension Integrates With Network Frontiers 26apos 3B Unified Compliance Framework To Simplify Compliance Challenges Reduce Costs And Harmonize Cont 50316 6